In a significant move to ease healthcare costs, Trump has announced new pricing agreements with nine mid-sized drugmakers, projected to save Americans approximately $600 billion. This expansion of the Most Favored Nation (MFN) pricing program includes firms like Teva and Astellas, and aims to lower prescription drug prices for a broad array of medications. Trump celebrated these agreements as a major step towards improving healthcare affordability, asserting that nearly 90% of prescription drugs are now covered under these new deals. The announcements came amid his effort to gain an electoral advantage in the upcoming midterms.